[*] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

Exhibit 10.45

AMENDMENT 1 TO EXCLUSIVE LICENSE AGREEMENT

This Amendment (the “Amendment”) is dated and effective as of the last date of
signature (the “Amendment Effective Date”) by and between Memorial Sloan
Kettering Cancer Center, a New York not-for-profit corporation with principal
offices at 1275 York Avenue, New York, NY 10065, The Rockefeller University, a
New York not-for-profit corporation with principal offices at 1230 York Avenue,
New York, NY 10065, Rutgers, The State University of New Jersey, having its
statewide Office of Technology Commercialization at 3 Rutgers Plaza, New
Brunswick, New Jersey 08901, and University of Bonn, all of which will be
collectively referred to as “Institutions” and Aduro Biotech, Inc., a
corporation with principal offices located at 626 Bancroft Way, #3C, Berkeley,
CA 94710 (“Licensee).

Whereas the Institutions and Licensee entered into an Exclusive License
Agreement for Institutions’ Technology “Compositions & Methods for Altering
Second Messenger Signaling,” effective as of December 18, 2014 (the “License
Agreement”); and

WHEREAS, the Institutions and Licensee desire to amend Exhibit C of the License
Agreement to include reference to additional proprietary cyclic dinucleotide
structures of Licensee.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which is acknowledged, the parties agree as follows:

1.

Exhibit C. The following structures are added to Exhibit C, Aduro Proprietary
Cyclic Dinucleotide Structures:

[*]

 

2.

Governing Law; Disputes. Sections 16.7 and 18.1 of the License Agreement shall
apply to any disputes arising from this Amendment.

3.

Entire Agreement. This Amendment and the License Agreement shall constitute the
entire agreement between the parties hereto pertaining to the subject matter
hereof and thereof.

4.

Severability. If any provision of this Amendment is found to be illegal or
unenforceable, the other provisions shall remain effective and enforceable to
the greatest extent permitted by law.

5.

No Waiver. Other than as expressly set forth herein, this Amendment does not
waive or modify any portion of the License Agreement, which otherwise remain in
full force and effect. No waiver of any provision of the License Agreement or
this Amendment may be made except in a writing signed by the Institutions and
Licensee.

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, authorized representatives of the parties have signed and
dated this Agreement below.

 

ADURO BIOTECH, INC.

 

MEMORIAL SLOAN KETTERING CANCER CENTER

 

 

 

 

By:

/s/ Greg Schafer

 

By:

/s/ Gregory Raskin

Name:

Greg Schafer

 

Name:

Gregory Raskin, M.D.

Title:

COO

 

Title:

Vice President,Technology Development

 

 

 

 

Memorial Sloan Kettering Cancer Center

Date:

May 8, 2016 / 11:44:59 AM ET

, 2016

 

 

 

 

 

 

Date:

5/11

, 2016

 

 

 

 

THE ROCKEFELLER UNIVERSITY

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Kathleen A. Denis

 

 

 

Name:

Kathleen A. Denis

 

 

 

Title:

Associate Vice President

 

 

 

 

 

 

 

 

Date:

18 May

, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

RUTGERS UNIVERSITY

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ S. David Kimball

 

 

 

Name:

S. David Kimball, Ph.D.

 

 

 

Title:

Associate Vice President

 

 

 

 

Research Commercialization

 

 

 

 

 

 

 

 

Date:

5/18/16

, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

THE UNIVERSITY OF BONN

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Rüdiger Mull

 

 

 

Name:

Rüdiger Mull

 

 

 

Title:

Rheinische

 

 

 

 

Friedrich-Wilhelms-Universität

 

 

 

 

Der Kanzler

 

 

 

 

 

 

 

 

Date:

5/27/

, 2016